The Biomedical Advanced Research and Development Authority (BARDA) has selected Allucent as part of a five-year agreement in the US for its new Decentralized Clinical Operations for Healthcare and Research (D-COHRe) initiative.
The initiative aims to support medical countermeasure development and enhance public health emergency preparedness.
Go deeper with GlobalData
Under the D-COHRe initiative, Allucent will enhance its decentralised clinical study capabilities, leveraging advancements in healthcare to build sustainable capacity and evaluate medical countermeasures in real-world settings.
The focus will be on deploying hybrid and fully decentralised trials, as well as employing home health, telehealth, mobile health, and alternative research sites.
Allucent will support these trials with secure data collection technology, participant engagement tools, and research services to ensure the enrolment and retention of participants.
Throughout the five-year programme, the company will innovate within decentralised care capabilities to conduct efficient and relevant research.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe company will also identify challenges in implementing decentralised trials and monitor the model’s success and sustainability.
Funding for this project is provided by the US Department of Health and Human Services’ Administration for Strategic Preparedness and Response.
Allucent chairman and CEO Mark Goldberg said: “In the wake of the Covid-19 pandemic, there is a pressing need and an unprecedented opportunity to realise the potential of decentralised clinical trials.
“Allucent is proud to partner with BARDA on this important initiative to bolster pandemic preparedness by enhancing decentralised clinical study capabilities. We look forward to applying our decentralised trial expertise to validate, pilot, and implement new products, technologies, and approaches intended for decentralised use, with the agility needed during a public health emergency.”
In May 2024, Allucent secured a $25.5m Biomedical Advanced Research and Development Authority (BARDA)-funded grant to support a decentralised Covid-19 vaccine clinical trial.
